AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Although great progress has been made in the field of siRNA gene therapy, safe, efficient, and targeted delivery of siRNA are still major challenges in siRNA therapeutics.
We developed an up-conversion nanoparticle-based nanocage system. This system protected the siRNA from being degraded by nucleases in organisms and selectively delivered the siRNAs to the tumor sites, due to modifications of targeted molecules on the surfaces of nanocages and local inhalation.
The siRNAs delivered by the up-conversion nanoparticle nanocages were protected from degradation in transit to the tumor sites, where they accumulated. Compared with the passive target and control groups, the up-conversion nanoparticles based on the nanocage system showed a tumor suppressive effect after approximately 3 weeks of treatment.
The up-conversion nanoparticle nanocages efficiently delivered vascular endothelial growth factor siRNAs to tumor sites. Mice with lung tumors treated with tumors targeting up-conversion nanoparticle nanocages showed steady body weight changes, high tumor inhibition ratios, and longer survival times.
Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001; 344: 783-92.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
He TC, Zhou SB, da Costa LT, Yu J, Kinzler KW. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95: 2509-14.
Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Del Rev. 2001; 47: 113-31.
Park, Park T, Jeong J, Kim S. Current status of polymeric gene delivery systems. Adv Drug Del Rev. 2006; 58: 467-86.
Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin JR. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15: 541-55.
Fischer D, Bieber T, Li YX, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999; 16: 1273-9.
Riley M, Vermerris W. Recent advances in nanomaterials for gene delivery-a review. Nanomaterials. 2017; 7: 94.
Gao S, Tang G, Hua D, Xiong R, Han J, Jiang S, et al. Stimuliresponsive bio-based polymeric systems and their applications. J Mater Chem B. 2019; 7: 709-29.
Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuechel R. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Del Rev. 2019; 138: 302-25.
Hu Q, Li H, Wang L, Gu H, Fan C. DNA nanotechnology-enabled drug delivery systems. Chem Rev. 2019; 119: 6459-506.
Bruun J, Larsen TB, Jolck RI, Eliasen R, Holm R, Gjetting T, et al. Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells. Int J Nanomedicine. 2015; 10: 5995-6008.
Ahmed M, Kumar G, Navarro G, Wang YG, Gourevitch S, Moussa MH, et al. Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy. PLoS One. 2015; 10: e0128910.
Arami S, Mahdavi M, Rashidi MR, Fathi M, Hejazi MS, Samadi N. Novel polyacrylate-based cationic nanoparticles for survivin siRNA delivery combined with mitoxantrone for treatment of breast cancer. Biologicals. 2016; 44: 487-96.
Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. Acs Nano. 2019; 13: 4028-40.
Lin QY, Jin CS, Huang H, Ding LL, Zhang ZH, Chen J, et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small. 2014; 10: 3072-82.
Xu ZH, Wang YH, Zhang L, Huang L. Nanoparticledelivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. Acs Nano. 2014; 8: 3636-45.
Bremer C, Tung C-H, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001; 7: 743-8.
Alhasan AH, Patel PC, Choi CHJ, Mirkin CA. Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small. 2014; 10: 186-92.
Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. Acs Nano. 2012; 6: 2174-88.
Choi KY, Silvestre OF, Huang XL, Min KH, Howard GP, Hida N, et al. Versatile RNA Interference nanoplatform for systemic delivery of RNAs. ACS Nano. 2014; 8: 4559-70.
Conde J, Bao C, Tan Y, Cui D, Edelman ER, Azevedo HS, et al. Tumor targeting: dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells (Adv. Funct. Mater. 27/2015). Adv Funct Mater. 2015; 25: 4183-94.
Creative Commons Attribution-NonCommercial 4.0 International License
京公网安备11010802044758号